pentobarbital will lessen the extent or result of buprenorphine subdermal implant by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Observe people by now on buprenorphine subdermal implant who have to have newly-initiated treatment with CYP3A4 inducer for indicators and symptoms of withdrawal.In clients with